Jeffery H. Moran
Assistant Professor
Also affiliated: Lawrence Livermore National Laboratory (2012); Arkansas Children's Hospital (2011–2021); University of Helsinki (2009); Monroe University (2013); Central Michigan University (2020); Universidad de Salamanca (1986); University of Toronto (1965–1966); Washington University in St. Louis (2009); University of Michigan (2012); University of Arkansas Medical Center (2018); Toronto General Hospital (1965–1966); Center for Environmental Health (2004); Cayman Chemical (United States) (2012); Arkansas Cardiology (2012); nPoint (United States) (2021–2026); Michigan United (2020); Arkansas State Crime Laboratory (2011–2012); Hospital de Cruces (1987); Jeffrey Modell Foundation (2013); Arkansas Department of Agriculture (2013–2025); Public Risk Management Association (2006); Arkansas Department of Health (2007–2018)
Faculty Researcher
Pharmacology & Toxicology, College of Medicine
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jeffery H. Moran investigates the pharmacological effects and toxicity of various substances, with a particular focus on novel synthetic opioids and cannabinoids. His research explores the antinociceptive properties, dependence potential, and withdrawal symptoms associated with compounds like furanyl fentanyl and acryl fentanyl in preclinical models. Moran also studies the pharmacodynamics and metabolism of therapeutic agents, including the deuterated form of buprenorphine, examining its resistance to metabolism into active metabolites in rats.
His work extends to the development and validation of analytical methodologies for forensic investigations, such as hands-free urine testing technology for drug-facilitated crime analysis. Moran also contributes to medical education through curriculum development for undergraduate students and has published on topics ranging from acetaminophen safety in patients with cirrhosis to the pharmacokinetics of bleomycin in vascular malformations. His scholarship metrics include an h-index of 29 and over 3,700 citations, reflecting a significant body of published work.
Metrics
- h-index: 29
- Publications: 84
- Citations: 3,777
Selected Publications
-
Interoceptive effects of N1-substituted lysergamides in rats: role of agonist affinity at 5-HT receptors and in vivo metabolism to lysergic acid diethylamide (LSD) (2026)
-
Co-occurring substance use disorders and the compounding effect of kratom on serious mental illness, US, 2021–2023 (2026)
-
Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses (2026)
-
Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption (2025)
-
Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice (2025)
-
Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations (2023)
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)
-
Development of a clinical and translational research curriculum for undergraduate students (2023)
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2022)
-
Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations (2022)
-
The Spice of Death (2021)
-
Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis (2021)
-
55715 Quantification of Neonatal THC Exposure Following Prenatal Marijuana Use (2021)
-
Modifying laboratory testing via home brew during the COVID-19 pandemic (2021)
-
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome (2019)
Grants & Funding
As listed on this researcher's institutional profile.
- Reduced Temperature Thermal Ablation for HCC and other Liver Tumors NIH Co-Investigator
- Metabolomics of menthol cigarette smoking and risk for aggressive prostate cancer among African-American men US Department of Defense Principal Investigator
- HEAL Initiative: Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial Clinical Site NIH Co-Investigator
- Synthetic Cannabinoid Toxicity: Role of Biotransformation NIH Co-Investigator
Collaboration Network
Top Collaborators
- Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
- The Spice of Death
- Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations
- Modifying laboratory testing via home brew during the COVID-19 pandemic
- Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
- Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
- Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
- Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations
- Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
- Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
- Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations
- Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses
Similar Researchers
Based on overlapping research topics